Perrigo/$PRGO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Perrigo

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Ticker

$PRGO
Sector

Primary listing

NYSE

Employees

8,379

Headquarters

Dublin, Ireland

Perrigo Metrics

BasicAdvanced
$3.1B
-
-$0.58
0.47
$1.13
5.12%

What the Analysts think about Perrigo

Analyst ratings (Buy, Hold, Sell) for Perrigo stock.

Bulls say / Bears say

Adjusted diluted EPS surged 106.9% year-over-year to $0.60 in Q1 2025, driven by expanded margins and lower interest expense, underscoring strong earnings leverage (Perrigo Q1 Release).
Management reaffirmed full-year 2025 adjusted EPS guidance of $2.90–$3.10 (13%–21% growth), showing confidence in delivering steady earnings growth amid market uncertainty (Perrigo Q2 Release).
On May 31, 2025, the U.S. FDA approved and Perrigo launched a store-brand version of Flonase (fluticasone propionate nasal spray), expanding its respiratory care product line and strengthening its national brand position (Reuters).
Organic net sales dropped 0.4% in Q1 and were flat at -0.1% in Q2 2025, indicating continued weakness in consumer demand and persistent pricing challenges across core OTC categories (Perrigo Q1 Release) (Perrigo Q2 Release).
In the North America Consumer Self-Care Americas segment, organic net sales declined 1.9% in Q2 2025, attributed to lost distribution in Digestive Health and Oral Care, which weighed on private label volumes (Perrigo Q2 Release).
Adjusted gross margin narrowed by 250 basis points to 38.1% in Q2 2025, affected by isolated production scrap in infant formula and reduced overhead absorption in OTC and Oral Care, highlighting ongoing margin pressures despite cost-saving efforts (Perrigo Q2 Release).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.

Perrigo Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Perrigo Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PRGO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Sept16
Perrigo
DividendPayment
$0.29Per share
FAQs